David A Boothman
Overview
Explore the profile of David A Boothman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
4504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Runnebohm A, Wijeratne H, Justice S, Wijeratne A, Roy G, Singh N, et al.
bioRxiv
. 2024 May;
PMID: 38798459
Background: Triple negative breast cancer (TNBC), characterized by the lack of three canonical receptors, is unresponsive to commonly used hormonal therapies. One potential TNBC-specific therapeutic target is NQO1, as it...
2.
Chang M, Mahar R, McLeod M, Giacalone A, Huang X, Boothman D, et al.
Nutrients
. 2022 Jul;
14(15).
PMID: 35893874
The compound β-lapachone, a naturally derived naphthoquinone, has been utilized as a potent medicinal nutrient to improve health. Over the last twelve years, numerous reports have demonstrated distinct associations of...
3.
Lewis J, Forshaw T, Boothman D, Furdui C, Kemp M
Cell Syst
. 2021 Jan;
12(1):68-81.e11.
PMID: 33476554
Redox cofactor production is integral toward antioxidant generation, clearance of reactive oxygen species, and overall tumor response to ionizing radiation treatment. To identify systems-level alterations in redox metabolism that confer...
4.
Shukla K, Singh N, Lewis J, Tsang A, Boothman D, Kemp M, et al.
Front Oncol
. 2020 Dec;
10:536377.
PMID: 33262939
Head and Neck Squamous Cell Cancer (HNSCC) presents with multiple treatment challenges limiting overall survival rates and affecting patients' quality of life. Amongst these, resistance to radiation therapy constitutes a...
5.
Starcher C, Pay S, Singh N, Yeh I, Bhandare S, Su X, et al.
Front Oncol
. 2020 Sep;
10:1575.
PMID: 32974194
Ionizing radiation (IR) creates lethal DNA damage that can effectively kill tumor cells. However, the high dose required for a therapeutic outcome also damages healthy tissue. Thus, a therapeutic strategy...
6.
Torrente L, Prieto-Farigua N, Falzone A, Elkins C, Boothman D, Haura E, et al.
Redox Biol
. 2020 Feb;
30:101440.
PMID: 32007910
Alterations in the NRF2/KEAP1 pathway result in the constitutive activation of NRF2, leading to the aberrant induction of antioxidant and detoxification enzymes, including NQO1. The NQO1 bioactivatable agent β-lapachone can...
7.
Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, et al.
Nat Commun
. 2019 Jul;
10(1):3251.
PMID: 31324798
Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising...
8.
Zaman S, Yu X, Bencivenga A, Blanden A, Liu Y, Withers T, et al.
Mol Cancer Ther
. 2019 Jun;
18(8):1355-1365.
PMID: 31196889
Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy...
9.
Motea E, Huang X, Singh N, Kilgore J, Williams N, Xie X, et al.
Clin Cancer Res
. 2019 Jan;
25(8):2601-2609.
PMID: 30617135
Purpose: Development of tumor-specific therapies for the treatment of recalcitrant non-small cell lung cancers (NSCLC) is urgently needed. Here, we investigated the ability of β-lapachone (β-lap, ARQ761 in clinical form)...
10.
Lewis J, Singh N, Holmila R, Sumer B, Williams N, Furdui C, et al.
Semin Radiat Oncol
. 2018 Dec;
29(1):6-15.
PMID: 30573185
Nicotinamide adenine dinucleotide (NAD) metabolism is integrally connected with the mechanisms of action of radiation therapy and is altered in many radiation-resistant tumors. This makes NAD metabolism an ideal target...